ERAS-0015 pan-RAS inhibitor shows early clinical responses — expansion cohort data will determine whether depth and durability justify Phase 3 advancement

Bull

A positive readout would show confirmed objective response rates meaningfully above historical chemotherapy benchmarks in key indications such as KRAS G12X NSCLC and PDAC, with durable responses extending beyond six months and a clean safety profile at the 24–32 mg QD recommended doses. This would validate ERAS-0015 as a best-in-class pan-RAS inhibitor with differentiated breadth across RAS mutation subtypes, de-risk Phase 3 design decisions, and materially strengthen the case for combination strategies already being explored with pembrolizumab and vopimetostat.

Bear

A disappointing outcome would feature low or transient response rates that reflect the intrinsic resistance mechanisms common to RAS-targeted agents, including rapid acquired resistance through secondary RAS mutations or bypass pathway activation. The most likely failure modes are shallow responses that do not deepen over time, short progression-free survival driven by adaptive MAPK reactivation, or emergence of on-target toxicities at efficacious doses that compress the therapeutic window and complicate Phase 3 dose selection.